ResMed Inc. (NYSE:RMD) reported EPS of 44 cents in the third quarter of fiscal 2012, beating the Zacks Consensus Estimate of 41 cents and also the year-ago EPS by 29%. Apart from increased sales and higher margin, a 6.4% fall in shares outstanding contributed to the bottom line improvement.
Revenues increased 11% year over year (up 13% at constant exchange rates or CER) to $349.1 million and surpassed the Zacks Consensus Estimate of $340 million. Based on a favorable product mix and vastly … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards